MUDr. Ivanna Boichuk
Department of Internal Medicine, Hematology and Oncology
e‑mail: | 454072@mail.muni.cz |
---|
Total number of publications: 16
2025
-
MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
Hematological Oncology, year: 2025, DOI
2024
-
CIRCULATING TUMOR CELLS HAVE HIGH PROGNOSTIC SIGNIFICANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH PARASKELETAL OR EXTRAMEDULLARY PLASMACYTOMAS
Year: 2024, type: Conference abstract
-
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Blood Cancer Journal, year: 2024, volume: 14, edition: 1, DOI
-
Del(1p32) is an early and high-risk event in relapsed multiple myeloma patients with extraosseous plasmacytomas
Year: 2024, type: Conference abstract
-
EFFICACY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE REGIMEN IN DARATUMUMAB-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE ANALYSIS
Year: 2024, type: Conference abstract
-
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
European Journal of Haematology, year: 2024, volume: 113, edition: 6, DOI
-
EL(1P32) IS AN EARLY AND HIGHRISK EVENT IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH EXTRAOSSEOUS PLASMACYTOMAS
Year: 2024, type: Conference abstract
-
Kryoglobulinémie z úhlu pohledu jednotlivých medicínských odborností
Transfuze a hematologie dnes, year: 2024, volume: 30, edition: 4, DOI
-
Úspěšná léčba relapsu Waldenströmovy makroglobulinemie (WM) inhibitory proteazomu
Klinická onkologie, year: 2024, volume: 37, edition: 6, DOI
-
Úspěšná léčba relapsu Waldenströmovy makroglobulinemie inhibitory proteazomu (bortezomibem a následně ixazomibem) v kombinaci s rituximabem a dexametazonem. Popis případu a přehled přínosu inhibitorů proteazomu pro Waldenströmovu makroglobulinemii
Klinická onkologie, year: 2024, volume: 37, edition: 6, DOI